Tirzepatide is a dual GLP-1/GIP agonist it addresses appetite, insulin sensitivity, fat metabolism, and energy expenditure simultaneously Cagrilintide targets amylin receptors in the brain for powerful appetite suppression, but without the broader metabolic benefits seen with Tirzepatide
Stay informed on the PCAC timeline
AOD9604 and 3-AR Knockout Research Research using 3-adrenergic receptor knockout mice established that AOD9604s chronic in vivo lipolytic actions are mediated in part by modulating the expression of 3-AR in adipose tissue a mechanism shared with intact hGH with the restoration of depressed 3-AR RNA levels in obese animals to lean-comparable levels identified as a key pathway of sustained lipolytic sensitisation
Patients in the third month of their protocol often describe the change not just as less pain but as a qualitative shift in how the injured area functions by month three: more fluid movement, faster recovery, and less restriction than before the protocol started
Refrigerate after reconstitution and use within 30 days
Potential Benefits Increases aerobic capacity and endurance performance by activating the same metabolic pathways engaged during sustained aerobic exercise training
